Journal
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
Volume 108, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.msec.2019.110191
Keywords
Drug release; alpha CT1 peptide; Glioblastoma; Cancer stem cell
Categories
Funding
- National Institutes of Health [R41 CA217503, R21 NS107941, R43 CA195937, R21 CA216768, R01 HL56728, ROl HL132236]
Ask authors/readers for more resources
Effective therapeutic delivery of peptide and protein drugs is challenged by short in vivo half-lives due to rapid degradation. Sustained release formulations of alpha CT1, a 25 amino acid peptide drug, would afford lower dosing frequency in indications that require long term treatment, such as chronic wounds and cancers. In this study, rhodamine B (RhB) was used as a model drug to develop and optimize a double emulsion-solvent evaporation method of poly(actic-co-glycolic acid) (PLGA) nanoparticle synthesis. Encapsulation of alpha CT1 in these nanoparticles (NPs) resulted in a sustained in vitro release profile over three weeks, characterized by an initial burst release of approximately 50% of total encapsulated drug over the first three days followed by sustained release over the remaining two and a half weeks. NP uptake by glioblastoma stem cells was through endocytosis and RhB and alpha CT1 were observed in cells after at least 4 days.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available